These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22083818)

  • 1. Profiling of urine using ProteinChip® technology.
    Woodbury RL; McCarthy DL; Bulman AL
    Methods Mol Biol; 2012; 818():97-107. PubMed ID: 22083818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis.
    Papale M; Pedicillo MC; Thatcher BJ; Di Paolo S; Lo Muzio L; Bufo P; Rocchetti MT; Centra M; Ranieri E; Gesualdo L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):205-13. PubMed ID: 17613287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pretreatment protocols on human amniotic fluid protein profiling with SELDI-TOF MS using protein chips and magnetic beads.
    Deng B; Dong Z; Liu Y; Wang C; Liu J; Wang C; Qu X
    Clin Chim Acta; 2010 Aug; 411(15-16):1051-7. PubMed ID: 20361951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardized preprocessing of urine for proteome analysis.
    Fiedler GM; Ceglarek U; Leichtle A; Thiery J
    Methods Mol Biol; 2010; 641():47-63. PubMed ID: 20407941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF.
    Caffrey RE
    Methods Mol Biol; 2010; 641():167-83. PubMed ID: 20407947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine.
    Terracciano R; Pasqua L; Casadonte F; Frascà S; Preianò M; Falcone D; Savino R
    Bioconjug Chem; 2009 May; 20(5):913-23. PubMed ID: 19338374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
    Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker discovery in serum/plasma using surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry.
    Ndao M
    Methods Mol Biol; 2012; 818():67-79. PubMed ID: 22083816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis.
    Novikova SI; He F; Cutrufello NJ; Lidow MS
    Neurobiol Dis; 2006 Jul; 23(1):61-76. PubMed ID: 16549361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening of differentially expressed proteins associated with directional highly lymphatic metastasis in ovarian carcinoma cell lines using SELDI-TOF-MS technology].
    Guan X; Li DR; Wang Q; Li L; Ruan HY; Zhang W
    Ai Zheng; 2008 Nov; 27(11):1155-60. PubMed ID: 19000445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
    O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
    Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
    Calvano CD; Aresta A; Iacovone M; De Benedetto GE; Zambonin CG; Battaglia M; Ditonno P; Rutigliano M; Bettocchi C
    J Pharm Biomed Anal; 2010 Mar; 51(4):907-14. PubMed ID: 19939598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of secreted proteins from CHO cells using Surface-Enhanced Laser desorption ionization time-of-flight mass spectrometry.
    Kumar N; Maurya P; Gammell P; Dowling P; Clynes M; Meleady P
    Biotechnol Prog; 2008; 24(1):273-8. PubMed ID: 18163642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.
    Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Iwabuchi I; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Mori K; Yamaya K; Ohyama C
    Oncol Rep; 2009 Jan; 21(1):73-9. PubMed ID: 19082445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
    Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
    BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
    Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
    Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry.
    Schaub S; Wilkins J; Weiler T; Sangster K; Rush D; Nickerson P
    Kidney Int; 2004 Jan; 65(1):323-32. PubMed ID: 14675066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the SELDI ProteinChip human serum retentate by microcapillary liquid chromatography-tandem mass spectrometry.
    Zhou M; Prieto DA; Lucas DA; Chan KC; Issaq HJ; Veenstra TD; Conrads TP
    J Proteome Res; 2006 Sep; 5(9):2207-16. PubMed ID: 16944932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods.
    Johnston O; Cassidy H; O'Connell S; O'Riordan A; Gallagher W; Maguire PB; Wynne K; Cagney G; Ryan MP; Conlon PJ; McMorrow T
    Proteomics Clin Appl; 2011 Aug; 5(7-8):422-31. PubMed ID: 21751411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics.
    West-Nørager M; Kelstrup CD; Schou C; Høgdall EV; Høgdall CK; Heegaard NH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):30-7. PubMed ID: 17112795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.